Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD ZolgensmaⓇ - SMN1 gene replacement therapy Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT03381729 STRONG (COAV101A12102) Type 2 spinal muscular atrophy Phase 1 51 Safety and tolerability, incidence of adverse events Proportion of patients achieving Standing Milestone Change in Hammersmith Functional Motor Scale Open-label, single-arm, single-dose, intrathecal Patients with spinal muscular atrophy with 3 copies of SMN2 Cohort B: Q4-2019 (actual); Cohort C1: TBC Read-out Milesstone(s) Publication TBD 92 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation